VIP (Vasoactive Intestinal Peptide)

VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide from the secretin/glucagon peptide family, synthesised naturally in nerve cells and cells of the intestinal mucosa. In laboratory models it is studied as a ligand of the G protein-coupled VPAC1 and VPAC2 receptors. Once bound to these receptors, it activates the adenylate cyclase–cAMP signalling pathway, which is why it is often used as a tool in signal transduction and cell biology research. This information is provided for scientific context only.

In in vitro work, VIP is used to assess VPAC1/VPAC2 receptor interaction and activation of the adenylate cyclase–cAMP pathway in cell cultures. Research models analyse its role in immune modulation, neuroinflammatory and smooth muscle cell processes, and in intercellular signalling networks. Typical studies include assessing receptor binding, transcription factors and cytokine expression in cell lines (e.g. monocytes, macrophages or CHO cells expressing VPAC receptors). All of this is carried out exclusively in a laboratory setting.

The product is supplied as a lyophilised powder. Each vial contains 10 mg of VIP (vasoactive intestinal peptide) of ≥99% purity (HPLC). For laboratory work, the powder is reconstituted in bacteriostatic water, which is sold separately. The solvent is run slowly onto the side of the vial, and the vial is swirled gently (without whisking) until the peptide has fully dissolved.

Keep the unopened vial of dry powder in a refrigerator at +2 to +8 °C, protected from light. For longer storage, −20 °C in a freezer is recommended. Keep the reconstituted (dissolved) solution refrigerated and use it within the time set out in your research protocol. Avoid repeated freeze–thaw cycles to preserve the stability of the peptide and the reproducibility of your research.

In signal transduction research, VIP is often used together with VPAC1/VPAC2 receptor antagonists or selective agonists to separate the contribution of each receptor. In work on the adenylate cyclase–cAMP pathway, it is combined with cAMP assay reagents and PKA/EPAC pathway modulators. In immune modulation models, VIP is studied in cell cultures together with pro-inflammatory stimuli (e.g. LPS), assessing cytokine expression. These combinations are used in vitro only; no doses for humans or animals are intended.

Absolutely not. This product is sold exclusively for laboratory research and scientific experiments. It is not intended for human or animal consumption and is not a medicine, dietary supplement or cosmetic product.